This is the authors' abstract. We don't add key points for this paper.
Standard therapies for many common cancers remain toxic and are often ineffective. Cellular immunotherapy has the potential to be a highly targeted alternative, with low toxicity to normal tissues but a high capacity to eradicate tumor. In this chapter we describe approaches that generate cellular therapies using active immunization with cells, proteins, peptides, or nucleic acids, as well as efforts that use adoptive transfer of effector cells that directly target antigens on malignant cells. Many of these approaches are proving successful in hematologic malignancy and in melanoma. In this chapter we discuss the advantages and limitations of each and how over the next decade investigators will attempt to broaden their reach, increase their efficacy, and simplify their application.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Okur et al. (2010) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: